New approaches to symptomatic treatments for Alzheimer’s disease

by Jeffrey Cummings
Published 2021-01-01

Disease modification and Neuroprotection in neurodegenerative disorders

by Jeffrey Cummings
Published 2017-09-01

Correction to: New approaches to symptomatic treatments for Alzheimer’s disease

by Jeffrey Cummings
Published 2021-04-01

Assessing Clinical Change in Individuals Exposed to Repetitive Head Impacts: The Repetitive Head Impact Composite Index

by Charles Bernick, Charles Bernick, Guogen Shan, Lauren Bennett, Jay Alberts, Jeffrey Cummings, Jeffrey Cummings
Published 2021-07-01

Repurposed agents in the Alzheimer’s disease drug development pipeline

by Justin Bauzon, Garam Lee, Jeffrey Cummings
Published 2020-08-01

The “rights” of precision drug development for Alzheimer’s disease

by Jeffrey Cummings, Howard H. Feldman, Philip Scheltens
Published 2019-08-01

Sex Moderates Amyloid and Apolipoprotein ε4 Effects on Default Mode Network Connectivity at Rest

by Jessica Z. K. Caldwell, Xiaowei Zhuang, MacKenzie J. Leavitt, Sarah J. Banks, Jeffrey Cummings, Jeffrey Cummings, Dietmar Cordes, The Alzheimer's Disease Neuroimaging Initiative
Published 2019-08-01

Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels

by Victor Bloniecki, Dag Aarsland, Jeffrey Cummings, Kaj Blennow, Yvonne Freund-Levi
Published 2014-08-01

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

by Jeffrey Cummings, Paul Aisen, Cynthia Lemere, Alireza Atri, Marwan Sabbagh, Stephen Salloway
Published 2021-05-01

Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemp...

by Elizabeth Finger, Scott Berry, Jeffrey Cummings, Kristy Coleman, Robin Hsiung, Howard H. Feldman, Adam Boxer
Published 2018-09-01

The Alzheimer's Disease Cooperative Study Prevention Instrument Project: Longitudinal Outcome of Behavioral Measures as Predictors of Cognitive Decline

by Sarah Jane Banks, Rema Raman, Feng He, David P. Salmon, Steven Ferris, Paul Aisen, Jeffrey Cummings
Published 2014-12-01

An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home

by Gunnhild J. Hjetland, Gunnhild J. Hjetland, Gunnhild J. Hjetland, Inger Hilde Nordhus, Inger Hilde Nordhus, Ståle Pallesen, Ståle Pallesen, Jeffrey Cummings, Jeffrey Cummings, Rochelle E. Tractenberg, Rochelle E. Tractenberg, Eirunn Thun, Eirunn Thun, Eirin Kolberg, Elisabeth Flo
Published 2020-03-01

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery

by Yadi Zhou, Jiansong Fang, Lynn M. Bekris, Young Heon Kim, Andrew A. Pieper, James B. Leverenz, Jeffrey Cummings, Feixiong Cheng
Published 2021-01-01

Souvenaid in the management of mild cognitive impairment: an expert consensus opinion

by Jeffrey Cummings, Peter Passmore, Bernadette McGuinness, Vincent Mok, Christopher Chen, Sebastiaan Engelborghs, Michael Woodward, Sagrario Manzano, Guillermo Garcia-Ribas, Stefano Cappa, Paulo Bertolucci, Leung-Wing Chu
Published 2019-08-01

On the path to 2025: understanding the Alzheimer’s disease continuum

by Paul S. Aisen, Jeffrey Cummings, Clifford R. Jack, John C. Morris, Reisa Sperling, Lutz Frölich, Roy W. Jones, Sherie A. Dowsett, Brandy R. Matthews, Joel Raskin, Philip Scheltens, Bruno Dubois
Published 2017-08-01

FLAME: A computerized neuropsychological composite for trials in early dementia

by Helen Brooker, Gareth Williams, Adam Hampshire, Anne Corbett, Dag Aarsland, Jeffrey Cummings, Jose Luis Molinuevo, Alireza Atri, Zahinoor Ismail, Byron Creese, Tormod Fladby, Charlotte Thim‐Hansen, Keith Wesnes, Clive Ballard
Published 2020-01-01